{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:33:45Z","timestamp":1791999225708,"version":"4.4.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010886","name":"Weifang Medical University","doi-asserted-by":"publisher","award":["2023YJSCX023"],"award-info":[{"award-number":["2023YJSCX023"]}],"id":[{"id":"10.13039\/501100010886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>With the extensive clinical application of immune checkpoint inhibitors (ICIs), immune-related adverse events (irAEs) associated with these agents have increasingly garnered significant attention. Unlike other irAEs, endocrine irAEs are mostly irreversible, with variable and nonspecific symptoms, which poses challenges for clinicians in diagnosis. As a result, this study leveraged the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER) pharmacovigilance databases to conduct an in-depth investigation into adverse events induced by PD-1\/PD-L1 inhibitors, with a focus on irAEs induced by PD-1\/PD-L1 inhibitors. This study pioneers the systematic cross-database validation of endocrine irAEs induced by PD-1\/PD-L1 inhibitors. The integration of data from the JADER offers unique safety insights for Asian populations, bolsters global pharmacovigilance efforts, and uncovers regional variations in irAEs reporting. Notably, this study revealed a higher prevalence of endocrine irAEs among men aged over 50 years receiving PD-1\/PD-L1 inhibitors. Both PD-1 and PD-L1 inhibitors are strongly associated with thyroid dysfunction, adrenal insufficiency, and pituitary inflammation. Additionally, it identifies several previously undocumented endocrine irAEs. This result unearthed safety signals hitherto unreported in drug inserts, underscoring the imperative for updating the safety labeling of PD-1\/PD-L1 inhibitors with respect to endocrine irAEs. The emergence of off-label uses further underscores the need for additional clinical trials to assess their efficacy and safety.<\/jats:p>","DOI":"10.1371\/journal.pone.0340794","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:33:17Z","timestamp":1767983597000},"page":"e0340794","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Endocrine advantages of PD-1\/PD-L1 therapy: Comparative analysis of FAERS-JADER"],"prefix":"10.1371","volume":"21","author":[{"given":"Yuxuan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8240-4768","authenticated-orcid":true,"given":"Lili","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"1","key":"pone.0340794.ref001","doi-asserted-by":"crossref","first-page":"22199","DOI":"10.1038\/s41598-024-72864-4","article-title":"Clinical characteristics and influencing factors of anti-PD-1\/PD-L1-related severe cardiac adverse event: based on FAERS and TCGA databases","volume":"14","author":"X Cheng","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0340794.ref002","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"C Robert","year":"2020","journal-title":"Nat Commun"},{"key":"pone.0340794.ref003","doi-asserted-by":"crossref","first-page":"956090","DOI":"10.3389\/fimmu.2022.956090","article-title":"The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application","volume":"13","author":"J-L Huo","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"pone.0340794.ref004","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.3390\/cancers14112687","article-title":"Clinical presentation of immune-related endocrine adverse events during immune checkpoint inhibitor treatment","volume":"14","author":"JHL Chieng","year":"2022","journal-title":"Cancers (Basel)"},{"key":"pone.0340794.ref005","doi-asserted-by":"crossref","first-page":"731798","DOI":"10.3389\/fphar.2021.731798","article-title":"PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy","volume":"12","author":"J Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"pone.0340794.ref006","doi-asserted-by":"crossref","first-page":"1157805","DOI":"10.3389\/fendo.2023.1157805","article-title":"Endocrine side effects of immune checkpoint inhibitors","volume":"14","author":"Z Cardona","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"pone.0340794.ref007","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"J Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"pone.0340794.ref008","article-title":"Endocrine complications of immunotherapies: a review","volume":"21","author":"R Hattersley","year":"2021","journal-title":"Clin Med (Lond)"},{"issue":"7","key":"pone.0340794.ref009","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2174\/0113894501290296240327081624","article-title":"Drug repurposing using FDA Adverse Event Reporting System (FAERS) database","volume":"25","author":"R Morris","year":"2024","journal-title":"Curr Drug Targets"},{"issue":"7","key":"pone.0340794.ref010","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"T Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"issue":"2","key":"pone.0340794.ref011","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pds.4944","article-title":"Quality evaluation of the Japanese Adverse Drug Event Report database (JADER)","volume":"29","author":"M Tsuchiya","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0340794.ref012","doi-asserted-by":"crossref","DOI":"10.1177\/03946320251327618","article-title":"Pharmacovigilance study of immunomodulatory drug-related adverse events using spontaneous reporting system databases","volume":"39","author":"S Nakao","year":"2025","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"1","key":"pone.0340794.ref013","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"DB Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"9","key":"pone.0340794.ref014","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.eprac.2024.05.014","article-title":"Immune checkpoint inhibitors-associated diabetes and ketoacidosis were found in FDA Adverse Event Reporting System: a real-world evidence database study","volume":"30","author":"M Han","year":"2024","journal-title":"Endocr Pract"},{"issue":"11","key":"pone.0340794.ref015","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1111\/bcp.14868","article-title":"Pharmacovigilance-based drug repurposing: the search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections","volume":"87","author":"R B\u00f6hm","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"pone.0340794.ref016","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ejhf.2401","article-title":"Primary endpoint adjudication: comparison between the expert committee and the regulatory MedDRA\u00ae coding in the MITRA-FR study","volume":"24","author":"A Facile","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"pone.0340794.ref017","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3390\/jcm7120542","article-title":"Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced cancer: a systematic review and meta-analysis of Phase III Randomized Clinical Trials","volume":"7","author":"A Grassadonia","year":"2018","journal-title":"J Clin Med"},{"issue":"1","key":"pone.0340794.ref018","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40360-025-00902-6","article-title":"Safety profile of faricimab: a multi-source pharmacovigilance analysis using FAERS and JADER","volume":"26","author":"C Liu","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"issue":"5","key":"pone.0340794.ref019","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"PN Taylor","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"pone.0340794.ref020","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s11154-025-09969-2","article-title":"Hypopituitarism in non-neuroendocrine pituitary tumors: a systematic review","volume":"26","author":"F Guerrero-P\u00e9rez","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"pone.0340794.ref021","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40618-019-01112-8","article-title":"Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study","volume":"43","author":"EM Presotto","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"pone.0340794.ref022","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"L-S Chang","year":"2019","journal-title":"Endocr Rev"},{"issue":"1","key":"pone.0340794.ref023","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s12020-021-02750-w","article-title":"Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy","volume":"74","author":"R Rubino","year":"2021","journal-title":"Endocrine"},{"issue":"2","key":"pone.0340794.ref024","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"A Kotwal","year":"2020","journal-title":"Thyroid"},{"issue":"1","key":"pone.0340794.ref025","doi-asserted-by":"crossref","first-page":"101411","DOI":"10.1016\/j.beem.2020.101411","article-title":"Check point inhibitors and autoimmunity: why endocrinopathies and who is prone to?","volume":"34","author":"R Percik","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"pone.0340794.ref026","doi-asserted-by":"crossref","first-page":"894015","DOI":"10.3389\/fonc.2022.894015","article-title":"Insights into the host contribution of endocrine associated immune-related adverse events to immune checkpoint inhibition therapy","volume":"12","author":"A Chye","year":"2022","journal-title":"Front Oncol"},{"issue":"7","key":"pone.0340794.ref027","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"JJ Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"pone.0340794.ref028","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.505","article-title":"Immune checkpoint inhibitors-induced endocrinopathies: assessment, management and monitoring in a comprehensive cancer centre","volume":"7","author":"O Elshafie","year":"2024","journal-title":"Endocrinol Diabetes Metab"},{"issue":"6","key":"pone.0340794.ref029","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"JR Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"pone.0340794.ref030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"HA Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0340794.ref031","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"AT Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"pone.0340794.ref032","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system","volume":"7","author":"Y Zhai","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"7","key":"pone.0340794.ref033","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eprac.2022.04.010","article-title":"American Association of Clinical Endocrinology Disease State Clinical Review: evaluation and management of immune checkpoint inhibitor-mediated endocrinopathies: a practical case-based clinical approach","volume":"28","author":"KCJ Yuen","year":"2022","journal-title":"Endocr Pract"},{"issue":"1","key":"pone.0340794.ref034","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/medicina61010123","article-title":"Endocrine adverse events in patients treated with immune checkpoint inhibitors: a comprehensive analysis","volume":"61","author":"M D\u00f6kmeta\u015f","year":"2025","journal-title":"Medicina (Kaunas)"},{"issue":"11","key":"pone.0340794.ref035","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s40618-022-01845-z","article-title":"Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS","volume":"45","author":"D Lu","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"pone.0340794.ref036","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","article-title":"Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis","volume":"15","author":"J Huang","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"3","key":"pone.0340794.ref037","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0145-2126(01)00126-6","article-title":"Hodgkin\u2019s disease in Asians: incidence patterns and risk factors in population-based data","volume":"26","author":"SL Glaser","year":"2002","journal-title":"Leuk Res"},{"issue":"7","key":"pone.0340794.ref038","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13780","article-title":"Analysis of real-world data to investigate the impact of race and ethnicity on response to programmed cell death-1 and programmed cell death-ligand 1 inhibitors in advanced non-small cell lung cancers","volume":"26","author":"KL Ayers","year":"2021","journal-title":"Oncologist"},{"issue":"6","key":"pone.0340794.ref039","first-page":"118","article-title":"Association of non-steroidal anti-inflammatory drug use with encephalopathy development: An analysis using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) databases","volume":"79","author":"K Kawada","year":"2024","journal-title":"Pharmazie"},{"key":"pone.0340794.ref040","article-title":"Abstracts of the 25th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Providence, Rhode Island, USA. August 16-19, 2009","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"pone.0340794.ref041","first-page":"331","article-title":"Adverse drug reaction risk measures: a comparison of estimates from drug surveillance and randomised trials","volume":"33","author":"R Beau-Lejdstrom","year":"2019","journal-title":"Pharmaceut Med"},{"issue":"2","key":"pone.0340794.ref042","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001754","article-title":"Strategies for improving the management of immune-related adverse events","volume":"8","author":"A Naing","year":"2020","journal-title":"J Immunother Cancer"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0344694","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000}}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:33:24Z","timestamp":1767983604000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340794"}},"subtitle":[],"editor":[{"given":"Rishi","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0340794","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}